NCT06372574 is a Phase 1 clinical trial of RO7617991 in Refractory Cancer, sponsored by Genentech, Inc..

Who is sponsoring NCT06372574?

NCT06372574 is sponsored by Genentech, Inc..

What drugs are being tested in NCT06372574?

Interventions in NCT06372574: RO7617991, Tocilizumab.

What condition does NCT06372574 study?

NCT06372574 studies Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult.

Is NCT06372574 still recruiting?

NCT06372574 is currently withdrawn. Last updated 3 September 2024.

Last reviewed 2024-09-03 · How we verify

NCT06372574

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Withdrawn Phase 1 Last updated 3 September 2024

What this trial tests

Phase 1 trial testing RO7617991 in Refractory Cancer. Withdrawn.

Timeline

30 September 2024

Primary endpoint
1 February 2028

1 February 2028

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Start date	30 September 2024
Primary completion	1 February 2028
Estimated completion	1 February 2028

Drugs / interventions tested

RO7617991 — full drug profile →
Tocilizumab (tocilizumab) — full drug profile →

Conditions studied

Refractory Cancer — all drugs for Refractory Cancer →
Recurrent Cancer — all drugs for Recurrent Cancer →
Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Refractory Cancer or Recurrent Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A\*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs).
Molldrem J, Zha D. · · 2024 · cited 5× · PMID 39594730 · DOI 10.3390/cancers16223776
Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.
Zhu W, Yi Q, Chen Z, Wang J, et al · · 2025 · cited 4× · PMID 39905312 · DOI 10.1186/s10020-025-01079-8

Verify or expand the search:

Other recruiting trials for Refractory Cancer

Currently open trials in the same condition.

NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
NCT06096038 — Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC · Phase 1, PHASE2 · recruiting
NCT06184035 — A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer · Phase 1, PHASE2 · recruiting
NCT05852717 — Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed · Phase 2 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06372574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 3 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing